more_reports

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Pharma Co. Reports Q1 Results and Advances Ersodetug Toward 2027 BLA Filing

  ()
Rezolute Inc. (RZLT:NASDAQ) shares are up on Phase 3 upLIFT topline expected mid-December 2026, FDA pre-BLA path for congenital HI, US$90M in cash, cash equivalents and marketable securities, and US$5B market opportunity in latest earnings.

Biopharma Co. Reports First Quarterly Revenue Above US$1 Billion as Acquisition Expands Portfolio

  ()
BioMarin Pharmaceutical Inc. (BMRN:NASDAQ) reported 32% revenue growth to US$1.025 billion in Q3 2026, supported by its Amicus acquisition, while expanding its Fabry disease pipeline and advancing VOXZOGO regulatory applications.

Pharma Co. Highlights Differentiated Design Following Setback for Competing Alzheimer's Drug

  ()
ProMIS Neurosciences Inc. (PMN:NASDAQ) highlights PMN310's antibody design and safety data following Acumen's Phase 2 setback, with a Q1 2027 Alzheimer's trial readout approaching.

Pharma Co. Raises 2026 Guidance Amid Pancreatic Rival Pressure

  ()
Novocure Ltd. (NVCR:NASDAQ) reported record Q3 2026 revenue of US$193M, raised full-year guidance, and secured Japan approval for Optune Pax despite competition from KRAS inhibitors in pancreatic cancer.

Biotech Co. Draws Split Analyst Ratings as RNA Pipeline Faces Clinical Tests

  ()
Sarepta Therapeutics Inc. (SRPT:NASDAQ) faces sharply divided analyst views, with H.C. Wainwright's US$5 Sell target contrasting with Wedbush's US$35 Buy target. Recent DM1 data, ELEVIDYS sales and upcoming results remain in focus.

AI Cuts Cancer Drug Discovery Costs From US$7.6 Million to US$1 Million in Just Two Years

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V; RKVTF:OTC; 7JO0:FSE) reported potent ATR inhibitor results from its kt-5000AI program after synthesizing 122 compounds, advancing its AI-powered drug discovery program toward development candidate selection.

Diabetes Cell Therapy Merger Nears Close Ahead of Q1 2027 First Patient Dosing

  ()
Sernova Biotherapeutics Inc. (SVA:TSX; SEOVF:OTCQB; PSH0:XETRA) is nearing its proposed merger with Seraxis to form BetaNova, a type 1 diabetes cell therapy company that plans to dose its first patient in Q1 2027. Find out why one analyst sees blockbuster potential in the combined pipeline.

NervGen Kicks Off Pivotal Phase 3 Test of NVG-291 in Chronic Spinal Cord Injury

  ()
NervGen Pharma Corp. (NGEN:NASDAQ) has dosed the first patient in its pivotal Phase 3 trial of NVG-291 in chronic spinal cord injury, with topline data expected in the first half of 2028. Find out why one newsletter writer says investors may face a long wait.

Sernova and Seraxis Bet on BetaNova to Take Diabetes Cell Therapy Into the Clinic

  ()
Sernova Biotherapeutics Inc. (SVA:TSX; SEOVF:OTCQB; PSH0:XETRA) and Seraxis Holdings Inc. are moving toward a merger to form BetaNova Biotherapeutics, with a type 1 diabetes cell therapy trial planned for early 2027. Find out why one analyst says Sernova found the right partner.

Can AI Find the Right Cancer Drug for the Right Patient? This Collaboration Is Putting It to Work

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V; RKVTF:OTCPK; 7JO0:FSE) partners with Celvion on AI-driven precision strategies for its ATR inhibitor.

Nektar's Phase 2b Data Shows Durable Eczema, Alopecia Response

  ()
Nektar Therapeutics (NKTR:NASDAQ) reports durable Phase 2b responses for rezpegaldesleukin in eczema and alopecia areata, as the Treg-targeted drug advances toward Phase 3.

Aldeyra Plans FDRR to Appeal FDA Reproxalap CRL for Dry Eye

  ()
Aldeyra Therapeutics Inc. (ALDX:NASDAQ) announces intent to submit Formal Dispute Resolution Request appealing March 2026 CRL for reproxalap in dry eye disease. Here is a plain-English guide to the FDA appeal process for investors.

Satellos Targets Untapped FSHD Market With FDA-Cleared IND for Phase 2 Trial

  ()
Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) received FDA clearance of its IND application for a planned Phase 2 study of forazapadin in FSHD; US$5M non-dilutive funding and quotes highlight regeneration potential where no therapies exist.

Rocket Pharmaceuticals Advances Danon Disease Gene Therapy Trial With FDA Alignment

  ()
Rocket Pharmaceuticals Inc. (RCKT:NASDAQ) receives FDA alignment to continue its Phase 2 RP-A501 trial for Danon disease, with nine additional patients expected to be treated by mid-2027.

Fennec Pharmaceuticals Reports PEDMARK Data Showing Reduced Hearing Loss in Japanese Study

  ()
Fennec Pharmaceuticals Inc. (FENC:NASDAQ;FRX:TSE) reports Phase 2 STS-J01 results for PEDMARK in Japan, with ASHA-defined hearing loss in 24% of patients versus a 56.4% benchmark.

Coya Enrolls 100 Patients in Phase 2/3 ALS Trial of COYA 302

  ()
Coya Therapeutics reaches 100-patient enrollment in its Phase 2/3 ALSTARS trial for COYA 302 in ALS, with full enrollment and topline data expected soon. Learn key catalysts for investors.

Medicus's Pfizer Deal Was Not a Fire Sale: A Strategic Bet on De-Risked ADC Drug

Contributed Opinion
  ()
Mike Sheikh shares his thoughts on Medicus Pharma Ltd. (MDCX:NASDAQ) after its recent deal with Pfizer Inc. (PFE:NYSE).

Coya Therapeutics Advances COYA 302 ALS Trial With 100th Participant

  ()
Coya Therapeutics Inc. (COYA:NASDAQ) enrolls its 100th participant in the Phase 2/3 ALSTARS trial of COYA 302 for ALS, with topline data expected in early Q2 2027.

Chart Buy Signals After Co. Targeting U.S. Alzheimer's Market Reports Final Major Regulatory Milestone

Contributed Technical Analyst Opinion
  ()
Technical Analyst Stewart Thomson reviews Grey Matters Health Inc. (GREY:CSE; AGNPF:OTCQB; AGW0:FRA) following its achievement of a major regulatory milestone.

Sernova-Seraxis Merger to Create BetaNova with US$10M for T1D Islet Trial

  ()
Sernova and Seraxis have entered into a definitive agreement to merge and create BetaNova Biotherapeutics, with US$10 million in financing to advance stem cell-derived islet therapy for type 1 diabetes, targeting Phase 1/2 data by mid-2027.

Biotechs Combine to Target Type 1 Diabetes Treatment

  ()
Sernova Biotherapeutics Inc. (SVA:TSX; SEOVF:OTCQB; PSH0:XETRA) has agreed to merge with privately held Seraxis to form BetaNova Biotherapeutics, a U.S.-based company advancing cell therapies for type 1 diabetes. Find out why one analyst calls the combination a good strategic move.

Ashok Kumar Thinks Full Enrollment Brings the Pivotal Readout Into View for Annovis Bio

Research Report
  ()
The path for Annovis Bio includes financing, persuasive cognition and function, balanced safety, a workable FDA filing path, and durable exclusivity.

REGENXBIO Faces Clinical Hold on RGX-121 but Duchenne BLA Advances

  ()
REGENXBIO's RGX-121 gene therapy faces an FDA clinical hold after spinal MRI findings, while the Duchenne muscular dystrophy program remains on track for its Q3 2026 BLA submission, along with wet AMD pivotal data expected in Q4.

Showing Results: 1 to 25 of 107 Next